SWOG clinical trial number
SWOG-9307

Extended Administration of Oral Etoposide And Oral Cyclophosphamide for the Treatment of Poor Prognosis Extensive Disease Small Cell Lung Cancer, Phase II Pilot

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Extended Administration of Oral Etoposide And Oral Cyclophosphamide for the Treatment of Poor Prognosis Extensive Disease Small Cell Lung Cancer, Phase II Pilot
Activated
07/01/1993
Closed
06/01/1996

Research committees

Lung Cancer

Publication Information Expand/Collapse

1999

Treatment of poor prognosis extensive disease small cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - A Southwest Oncology Group clinical and pharmacokinetic study.

SM Grunberg;JJ Crowley;KR Hande;DJ Giroux;NC Munshi;DHM Lau;LE Schroder;MH Zangmeister;SP Balcerzak;HE Hynes;DR Gandara Cancer Chemotherapy and Pharmacology 44:461-468

1997

Oral etoposide (VP) and oral cyclophosphamide (CP) for poor prognosis extensive disease (ED) small cell lung cancer (SCLC). A Southwest Oncology Group clinical and pharmacokinetic study.

SM Grunberg;D Rector;K Hande;R Livingston Lung Cancer 18(Suppl.1)(#85):24-25

1994

Extended oral etopside (E) and oral cyclophosphamide (C) for lung cancer

SM Grunberg;J Crowley;R Livingston Lung Cancer 11(Suppl.1):121(#464)

Other Clinical Trials

SWOG Clinical Trial Number
S2302

PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
95%
Open
Phase
SWOG Clinical Trial Number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open